glp-1 commercial glp 1 Ro serves up Super Bowl ad starring Serena Williams GLP-1 RA education – Monster of 2025: GLP-1 Ads

Physiol Genomics (2005) 22:13949

Vayena, E., Blasimme, A

Similarly, interrupted use was associated with increased MACE risk, with IRRs of 1.12 for one year and 1.16 for two years of interruption, with effect sizes differing modestly depending on prior treatment duration

The Basics at a Glance Generic name: Retatrutide (development code: LY3437943) Manufacturer: Eli Lilly and Company Drug class: Triple agonist (GLP-1/GIP/glucagon receptor agonist) Administration: Once-weekly subcutaneous injection Dosing range: 2mg to 12mg weekly (gradual titration over 12+ weeks) Half-life: Approximately 6 days (reaches steady state in 45 weeks) FDA status: Phase 3 clinical trials (TRIUMPH program) Expected approval: 20272028 How Retatrutide Differs from Other GLP-1 Medications To understand retatrutide, it helps to see where it fits in the evolution of GLP-1 class medications